Brokers Offer Predictions for RIGL Q1 Earnings

Key Points

• HC Wainwright projects Q1 2026 EPS of $0.95 and issued FY2027/FY2028 EPS forecasts of $3.85 and $4.42 (slightly trimmed), while the street consensus is a Moderate Buy with an average price target of $48.
• Rigel gave FY2026 revenue guidance of $275–$290M and expects positive net income, but recent GAAP EPS was boosted by an approximately $245.9M non‑cash deferred tax benefit and adjusted metrics were mixed, helping drive the stock down about 10%.
• Near‑term clinical catalyst: enrollment in the R289 lower‑risk MDS dose‑expansion is ongoing and management expects to select a recommended Phase 2 dose in H2 2026.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn $0.95 per share for the quarter. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' Q2 2026 earnings at $1.20 EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $4.42 EPS.

RIGL has been the subject of a number of other reports. Weiss Ratings reissued a "hold (c+)" rating on shares of Rigel Pharmaceuticals in a report on Thursday, January 22nd. Zacks Research raised shares of Rigel Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 18th. Cantor Fitzgerald boosted their target price on Rigel Pharmaceuticals from $32.00 to $38.00 and gave the stock a "neutral" rating in a report on Wednesday, November 5th. Citigroup restated a "buy" rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Wall Street Zen raised Rigel Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Sunday, December 21st. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $48.00.

Rigel Pharmaceuticals Stock Down 10.3%

Shares of RIGL opened at $29.63 on Thursday. Rigel Pharmaceuticals has a 12 month low of $15.50 and a 12 month high of $52.24. The stock has a market cap of $537.78 million, a price-to-earnings ratio of 1.57 and a beta of 1.10. The company has a 50-day moving average price of $37.46 and a two-hundred day moving average price of $37.38. The company has a quick ratio of 2.14, a current ratio of 2.28 and a debt-to-equity ratio of 0.25.

Institutional Trading of Rigel Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. AlphaQuest LLC lifted its stake in shares of Rigel Pharmaceuticals by 234.8% in the 3rd quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 775 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Rigel Pharmaceuticals by 400.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 1,020 shares during the last quarter. IFP Advisors Inc acquired a new position in Rigel Pharmaceuticals in the third quarter valued at about $55,000. CWM LLC boosted its holdings in Rigel Pharmaceuticals by 217.0% during the fourth quarter. CWM LLC now owns 1,791 shares of the biotechnology company's stock worth $77,000 after buying an additional 1,226 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Rigel Pharmaceuticals during the 3rd quarter worth about $62,000. Institutional investors own 66.23% of the company's stock.

Insider Activity at Rigel Pharmaceuticals

In related news, Director Walter H. Moos sold 4,000 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $36.36, for a total transaction of $145,440.00. Following the completion of the sale, the director directly owned 12,722 shares of the company's stock, valued at $462,571.92. The trade was a 23.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 9.48% of the stock is currently owned by corporate insiders.

Key Rigel Pharmaceuticals News

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Company reported record net product sales and provided FY2026 revenue guidance of $275–$290M and said it expects positive net income; this supports near-term revenue visibility and profitability outlook. PR Newswire: Q4/FY2025 Results & Guidance
• Positive Sentiment: Pipeline progress: enrollment in the R289 dose-expansion (lower‑risk MDS) is ongoing and management expects to select a recommended Phase 2 dose in H2 2026 — a potential clinical catalyst. Earnings Presentation / Slides
• Neutral Sentiment: Reported GAAP net income included a very large non‑cash deferred tax benefit (~$245.9M), which inflates headline EPS and complicates comparisons to analyst expectations; adjusted metrics showed a more muted beat/miss picture. MarketBeat: Earnings/Transcript
• Neutral Sentiment: Analysts and consensus view mixed — the street currently has a "Hold" consensus, and HC Wainwright published detailed quarterly and multi‑year EPS forecasts (Q1/Q2 2026 and FY2027/28 estimates). MarketBeat: Analyst Notes
• Negative Sentiment: HC Wainwright trimmed FY2027 and FY2028 EPS forecasts modestly (FY2027 to $3.85 from $3.92; FY2028 to $4.42 from $4.73), signaling slightly lower medium‑term profit expectations. MarketBeat: HC Wainwright Estimates
• Negative Sentiment: Adjusted/operational earnings metrics were mixed: Zacks flagged an EPS miss on the quarter vs. consensus (adjusted metrics), which alongside commentary that contract revenues are falling contributed to downward pressure. Zacks: Q4 Earnings Miss
• Negative Sentiment: Regulatory risk: a TipRanks piece highlights uncertainty around pursuing FDA Fast Track designations, introducing additional execution risk for the pipeline. TipRanks: FDA Fast Track Uncertainty
• Negative Sentiment: Market commentary (Seeking Alpha) emphasized the risk of falling contract revenues driving near‑term margin/revenue contraction, a factor cited by traders selling into the print. Seeking Alpha: Stock Slides on Outlook

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel's lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.